HIV-1 Induces Cytotoxic T Lymphocytes in the Cervix of Infected Women by Musey, Luwy et al.
 
293
 
J. Exp. Med. 
 
Ó
 
 The Rockefeller University Press • 0022-1007/97/01/293/11 $2.00
Volume 185, Number 2, January 20, 1997 293–303
 
HIV-1 Induces Cytotoxic T Lymphocytes in the Cervix of
Infected Women
 
By Luwy Musey, Yuxiang Hu, Linda Eckert, Michael Christensen, 
Tobi Karchmer, and M. Juliana McElrath
 
From the Departments of Medicine and Obstetrics and Gynecology, The University of Washington 
School of Medicine, Seattle, Washington 98195
 
Summary
 
Although T lymphocytes are present in the genital mucosa, their function in sexually transmit-
ted diseases is unproven. To determine if cervical T cells mediate HIV-specific cytolysis, mono-
nuclear cells in cytobrush specimens from HIV-1-infected women were stimulated in vitro
with antigen. Resultant cell lines lysed autologous targets expressing HIV-1 proteins in 12/19
(63%) subjects, and these responses were detected intermittently on repeated visits. All 8 sub-
jects with blood CD4
 
1
 
 counts 
 
>
 
500 cells/
 
m
 
l had HIV-1-specific cervical CTL, whereas only
4/11 with counts 
 
,
 
500 cells/
 
m
 
l had detectable responses (
 
P 
 
5
 
 0.008). Class II MHC–
restricted CD4
 
1
 
 CTL clones lysed targets expressing Env gp41 or infected with HIV-1. Class I
MHC-restricted CD8
 
1
 
 clones recognized HIV-1 Gag- or Pol-expressing targets, and the
epitopes were mapped to within 9–20 amino acids. Comparisons of intra-individual cervical
and blood CTL specificities indicate that epitopes recognized by CTL in the cervix were com-
monly recognized in the blood. These studies provide the first definitive evidence for an
MHC-restricted effector function in human cervical lymphocytes.
 
M
 
ore than 80% of HIV-1 transmissions occur through
heterosexual intercourse, and the risk for acquiring
infection by this route is at least twofold greater in women
than men (1). The presence of HIV-specific effector im-
mune responses at the site of transmission, the cervicovagi-
nal area, may be critical in women for the initial control of
infection and in the selection of strains which disseminate
systemically. Local antibodies, particularly IgA, are the pri-
mary effectors classically responsible for the elimination of
mucosal pathogens (2, 3).  Although specific IgA antibodies
are induced in HIV-1 infection, their presence in cervico-
vaginal fluid is neither correlated with reduced HIV-1 shed-
ding nor protection from vertical transmission in pregnant
women (4) and some investigations suggest that IgA may
invoke antibody-mediated enhancement of infection (5, 6).
Alternatively, mucosal T cells capable of both cytolytic ac-
tivity and cytokine production may actively participate in
the early defense against HIV-1 infection, as has been sug-
gested from recent findings in the macaque model of SIV
infection (7).
Intraepithelial and submucosal lymphocytes are present
in the cervix and vagina of healthy adult women (8–10),
and circumstantial evidence suggests that these cells partici-
pate in the immune response against foreign antigens. For
example, in association with human papilloma virus infec-
tion (11), tobacco smoking (12), and dysplasia (13, 14),
variations in the phenotypes of cervicovaginal T cell popu-
lations have been reported. Moreover, CD8
 
1
 
 T cells are
recruited to the squamocolumnar cervical junction in cer-
vical neoplasia (15). Recently, Olaitan et al. (16) found sig-
nificant alterations in the proportion of T lymphocytes,
Langerhans’ and plasma cells in the cervix of HIV-infected
women. Thus far, however, there is no evidence that mu-
cosal lymphocytes have an effector function, particularly
cytolytic, in HIV infection.
The purpose of this investigation was to determine the
presence and function of HIV-specific T cell responses in
the cervix of HIV-infected women. Unexpectedly, we
found that although CD3
 
1
 
 T cells comprise a small pro-
portion (
 
,
 
5%) of the cells obtained from a cervical cyto-
brush or biopsy, selected populations of both CD4
 
1
 
 and
CD8
 
1
 
 cells from these specimens were capable of HIV-
specific cytolytic activity upon in vitro antigen-specific stimu-
lation. We report the kinetics of responses in 19 HIV-
1-infected women, the gene products recognized by the
CTL, and the epitope specificity and MHC restriction pat-
terns at the clonal level. These findings are the first to es-
tablish a functional role for intraepithelial lymphocytes in
human cervical infection and indicate that the female geni-
tal mucosal system is armed not only with antibody but also
cellular effector immune responses.
 
Materials and Methods
 
Study Population.
 
23 females with HIV-1 infection, docu-
mented serologically by both HIV-1 EIA and Western blot, and 5
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HIV-1 seronegative female controls were enrolled in a longitudi-
nal study to examine HIV-1-specific immunological and virolog-
ical responses in the mucosal tissues. The University of Washing-
ton Human Subject Review Board approved all aspects of the
investigation, and written consent was obtained from the volun-
teers before initiation of the study. The study entailed monthly
visits by the volunteers to either the UW AIDS Vaccine Evaluation
Unit or the Northwest Family Center. When appointments were
missed, volunteers were rescheduled within 1–4 wk. At each visit,
a clinician performed a clinical evaluation, pelvic examination and
venipuncture. Peripheral blood T cell subset counts were measured
by standard flow cytometric analysis in the University of Wash-
ington Hematopathology Laboratory. Class I and class II HLA se-
rological typing was performed on PBMC at the Fred Hutchinson
Cancer Research Center Clinical Immunogenetics Laboratory.
 
Collection and Processing of Cervical Specimens.
 
Cervical speci-
mens were collected by cytobrush and biopsy. No cervical speci-
mens were taken from menstruating patients, if blood was visible
in the cervical area, or if the epithelium appeared disrupted. The
cytobrush was inserted just within the cervical os and rotated one
360
 
8
 
 turn. Any specimen with visible blood was discarded. Im-
mediately after sampling, the cytobrush was placed in a 15-ml
conical tube containing 3 ml of RPMI 1640 with 100 U/ml pen-
icillin, 100 
 
m
 
g/ml streptomycin, and 2.5 
 
m
 
g/ml amphotericin B
(Biowhittaker, Walkersville, MD), and placed on ice. The speci-
men was transported on ice to the laboratory and processed
within 3 h of collection. The cytobrush was gently rotated several
times in the transport media and then discarded. The cell suspen-
sion was centrifuged (330 
 
g
 
, 10 min), and the pellet was resuspended
in RPMI. Mononuclear cells were isolated by Ficoll-Hypaque
density centrifugation, washed twice, and filtered through sterile
cotton gauze to remove the majority of epithelial cells. After an
additional wash by centrifugation, the mononuclear cells were re-
suspended in RPMI containing 100 U/ml penicillin, 100 
 
m
 
g/ml
streptomycin, 10% heat-inactivated human AB serum (Biocell,
Palo Alto, CA), and 50 
 
m
 
M 
 
b
 
2-mercaptoethanol (Kodak, Roches-
ter, NY), subsequently referred as R-10 HS. Samples containing
red blood cells by light microscopy were discarded.
On selected volunteers, tissue biopsies of 
 
z
 
4 mm were ob-
tained with forceps from the transitional zone of the cervix. After
repeated washing to remove any contaminating blood, the cervi-
cal biopsies were gently pushed with a pestle through a 140-
 
m
 
m
screen to obtain a single cell suspension, and then washed by cen-
trifugation. Mononuclear cells were isolated by Ficoll-Hypaque
density centrifugation, filtered through sterile cotton gauze,
washed and resuspended in R-10 HS.
 
Flow Cytometry Analysis.
 
The following mouse anti–human
monoclonal antibodies were used to characterize subpopulations
of mucosal lymphocytes: anti-CD3 FITC/CD16 PE, anti-CD4
FITC/CD8 PE, anti-CD14 FITC/CD45 PE, anti-CD19 FITC,
and anti-TCR-
 
ab
 
 FITC/TCR-
 
gd
 
 PE (Becton-Dickinson, San
Jose, CA), and FITC-conjugated anti-mucosal lymphocyte anti-
gen (MLA-1) (Dako Corp., Carpenteria, CA). In brief, 10
 
5
 
 cells
were incubated with the mAb for 30 min at 4
 
8
 
C, washed with
PBS by centrifugation, fixed with 2% paraformaldehyde in PBS
and analyzed with a FACScan
 
Ò
 
 flow cytometer (Becton Dickin-
son). Samples were gated using the Consort-30 software (Becton
Dickinson), and the appropriate isotype IgG controls were used
to define background staining limits and quadrant markers. Scat-
ter gates were first chosen to analyze the lymphocyte fraction and
then expanded to include cells with greater forward and orthogo-
nal scatter. Cell phenotypes were assessed by bivariate plots of
FL-1 and FL-2 in logarithmic mode.
 
Recombinant Vaccinia Viruses.
 
Recombinant vaccinia vectors
(rVV)
 
1
 
 were used to express HIV-1 or control gene products in
target cells or monocyte stimulator cells. These included rVV en-
coding the full-length HIV-1
 
LAI
 
 envelope gp160 (vPE-16) (17),
serial deletions of the HIV-1
 
LAI 
 
gp160 (vPE-17, vPE-18, vPE8,
vPE21, vPE-22) (18), HIV-1
 
LAI
 
 
 
pol 
 
(vRT) (19), and the control
vector encoding lacZ (vSC-8) (20), which were kindly provided
by B. Moss (NIH, Bethesda, MD). The rVV containing HIV-1
 
LAI
 
gag
 
 (vDK-1) was provided by D. Kuritzkes (21), through the
NIH AIDS Reagent Repository. The vaccinia vector encoding
the three HIV-1
 
LAI
 
 genes 
 
env, gag, 
 
and
 
 pol
 
 (vv-EGP), was kindly
provided by D. Panacali (Therion Inc., Cambridge, MA), and the
rVV containing HIV-1 
 
gag
 
 p24 (vP1287) and 
 
gag 
 
p17 (vP1289)
by J. Tartaglia (Virogenetics, Inc., Troy, NY).
 
Synthetic HIV-1 Peptides.
 
Synthetic peptides, up to 20 amino
acids (aa) in length, corresponding to HIV-1 gene products were
provided by Dr. M. C. Walker (NIAID, Bethesda, MD) through
the NIH AIDS Reagent Repository, Dr. B. Walker (Massachu-
setts General Hospital, Boston, MA), and Dr. D. Lewinsohn
(Fred Hutchinson Cancer Research Center, Seattle, WA). Pep-
tides were reconstituted at a concentration of 1 mg/ml in 10%
DMSO (Sigma Chemical Co., St. Louis, MO) and sterile H
 
2
 
O,
and were used at a final concentration of 10 
 
m
 
g/ml to pulse target
cells for CTL assays.
 
In Vitro Stimulation of Effector CTL.
 
Fresh autologous PBMC
in RPMI (15 million in 3 ml) were allowed to adhere in a 6-well
tissue culture plate at 37
 
8
 
C and 5% CO
 
2
 
, and the nonadherent
cells were removed after 2 h with repeated washes. The adherent
monocytes were infected with vv-EGP (multiplicity of infection
of 10) for 14 h at 37
 
8
 
C. The infected monocytes were UV-irradi-
ated for 10 min, washed twice to remove any remaining nonad-
herent cells and free vaccinia virus, harvested gently with a cell
scraper, gamma-irradiated (3,000 rad) and used as stimulator cells.
Freshly isolated mucosal mononuclear cells or PBMC were
plated by limiting dilution in 96-well round-bottomed microtiter
plates. Irradiated monocytes (1,000 cells) infected with vv-EGP
and irradiated autologous PBMC (50,000 cells) feeder cells were
resuspended in R-10 HS with 50 U human recombinant IL-2
(rIL-2) (Chiron, Emeryville, CA) and added in a volume of 100
 
m
 
l to each microwell. The cultures were incubated at 37
 
8
 
C in 5%
CO
 
2
 
, and the wells were provided fresh media and rIL-2 twice
weekly. Cells demonstrating growth after 2–4 wk were restimu-
lated with 30 ng/ml OKT3 (Ortho Diagnostic System, Raritan,
NJ), fresh irradiated feeder cells, and expanded into 24-well tissue
culture plates (Costar, Cambridge, MA).
 
Preparation of Target Cells.
 
Epstein-Barr virus transformed B
lymphoblastoid cell lines (B-LCL) were established from periph-
eral blood mononuclear cells (PBMC) isolated from each subject
and maintained in RPMI 1640 supplemented with 10% FCS,
 
l
 
-glutamine, penicillin 100 U/ml, and streptomycin 100 
 
m
 
g/ml
(subsequently referred as R-10). Partially mismatched B-LCL
from donors RML and SCHU were kindly provided by R. Sili-
ciano (Johns Hopkins University, Baltimore, MD). Autologous
or allogeneic B-LCL were infected with rVV at a multiplicity of
infection of 1 for 16 h at 37
 
8
 
C, washed twice with R-10, and re-
suspended in 2 ml of R-10 before the CTL assay. To test effector
lysis of target cells infected with HIV-1, B-LCL were transduced
with a retroviral vector (LST4SN) containing the human CD4
 
1
 
Abbreviations used in this paper:
 
 aa, amino acids; rVV, recombinant vac-
cinia vectors. 
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gene (22), cultured in R-10 supplemented with 1.5 mg of G418
(neomycin) per ml, and selected by panning onto CD4 mAb–
coated MicroCellector flasks (Applied Immune Sciences, Santa
Clara, CA). Two million CD4-expressing LCL (B-LCL-CD4)
were infected in 24-well plates for 7 d with 200–400 TCID
 
50
 
 of
HIV-1
 
LAI
 
 or HIV-1 from the supernatant of a PBMC co-culture
(one passage) derived from patients with early HIV-1 infection
(no. 1002 and no. 1005), according to the previously described
method (22). HIV-1 infectivity of the B-LCL-CD4 was determined
by reverse transcriptase assay, as previously described (23). Unin-
fected B-LCL-CD4 were used as controls for the HIV-1-infected
targets. The erythroleukemia cell line K562 (ATCC CCL 243),
maintained in R-10, was used to measure NK cell lytic activity.
Uninfected and HIV-1 infected B-LCL-CD4, B-LCL infected
with various rVV, and K562 cells were labeled with 0.1 mCi
 
51
 
Na
 
2
 
CrO
 
4
 
 (NEN Products, Boston, MA) for 16 h. Thereafter,
cells were gently washed three times and resuspended in R-10 at a
concentration of 5 
 
3
 
 10
 
4
 
/ml.
 
CTL Chromium Release Assay.
 
Radiolabeled target cells were
plated at 5 
 
3
 
 10
 
3 
 
cells/well in 96-well round-bottomed plates.
Effector cells were added in triplicate to the wells at varying effec-
tor to target cell ratios (E/T) in a total volume of 200 
 
m
 
l. After a
5-h incubation at 37
 
8
 
C and 5% CO
 
2
 
, 30 
 
m
 
l of supernatant were
harvested from each well into Lumaplates (Packard, Meriden,
CT) and the 
 
51
 
Cr release was measured using a Topcount (Pack-
ard, Meriden, CT). In all experiments, spontaneous 
 
51
 
Cr release,
measured from control wells containing target cells with media
alone, was less than 25% of maximum lysis of target cells with 5%
Triton-X (Sigma). The percent specific lysis was calculated as fol-
lows: 100 
 
3
 
 (test release 
 
2
 
 spontaneous release)/(maximum re-
lease 
 
2
 
 spontaneous release). A positive response was defined as
(10% lysis of the target cells expressing HIV-1 gene products mi-
nus the appropriate control target cells.
 
Generation and Analysis of CTL Clones.
 
Wells containing cells
with HIV-1-specific cytolytic activity were plated at 1–3 cells per
well in round-bottomed 96-well plates (Costar, Cambridge, MA)
with 10
 
5 
 
freshly isolated allogeneic 
 
g
 
-irradiated PBMC feeder
cells, 25 U/ml rIL-2 and 30 ng/ml OKT3 in a total volume of
 
Table 1.
 
Cytolytic Responses of T Cells Isolated from Cervical Cytobrush Specimens in HIV-1-infected Women
 
Study Population Specimens HIV-1-Specific Lysis
 
*
 
NK Lysis
 
*
 
Volunteer
no. CD4 count
Clinical
course
No. evaluable/
no. collected
No. CTL
 
1
 
/
no. evaluable
HIV-1
Env
HIV-1
Gag
HIV-1
Pol
No. lysis
 
1
 
/
no. evaluable
 
cells/
 
m
 
l
 
704 673 oral/vag yeast 3/10 1/3
 
211
 
‡
 
1/3
775 569 vag yeast 1/3 1/1
 
122
 
ND
709 1377 diarrhea, resolved 5/10 2/5
 
111
 
1/5
710 722 asymptomatic 10/10 6/10
 
1
 
‡
 
1
 
‡
 
2
 
1/10
909 969 vag yeast 1/2 1/1
 
21
 
‡
 
2
 
0/1
742 500 asymptomatic 4/7 1/4
 
122
 
1/4
739 511 asymptomatic 2/3 1/2
 
1
 
‡
 
21
 
‡
 
0/2
741 563 asymptomatic 8/11 4/8
 
21
 
‡
 
2
 
4/8
738 339 asymptomatic 8/8 4/8
 
1
 
‡
 
11
 
‡
 
2/8
743 83 vag yeast 2/7 0/2
 
222
 
1/2
747 204 yeast, trichomonas 2/3 1/2
 
122
 
1/2
770 178 diarrhea, resolved 1/5 0/1
 
222
 
0/1
711 415 dysplasia, vag yeast 2/7 0/2
 
222
 
0/2
776 230 deceased 1/2 0/1
 
222
 
0/1
824 273 cervical dysplasia 2/3 0/2
 
222
 
0/2
840 49 vag yeast 1/2 0/1
 
222
 
0/1
888 471 asymptomatic 2/3 0/2
 
222
 
0/2
737 356 vag yeast 3/6 1/3
 
122
 
3/3
708 450 asymptomatic 6/6 2/6
 
1
 
‡
 
22
 
2/5
Total 
 
5 19 64/108 25/64 9/19 6/19 4/19 17/62
(59%) (39%) (47%) (32%) (21%) (27%)
Data shown for 19 of 23 women with at least one evaluable specimen on >2 visits.
*HIV-1-specific lysis defined by effector CTL recognition and lysis of autologous target cells expressing either HIV-1 Env, Gag, or Pol at an E/T of
1:1 to 5:1. NK lysis defined by cytotoxicity of K562 target cells at an E/T of 4:1.
‡HIV-1-specific CTL clones generated.
§ND, not done.296 HIV-1-Specific Cervical Cytotoxic T Lymphocytes
200 ml with R10-HS. HIV-specific lytic clones were expanded
over 2–4 wk into 24-well culture plates. Epitope mapping and
specific HLA restriction analysis were performed using autolo-
gous or HLA-mismatched allogeneic B-LCL infected with rVV
or pulsed with the appropriate peptide.
Statistical Analysis. Statistical analyses were performed using
Epi-Info6 software. The student t test was used to analyze nor-
mally distributed variables and the Mann-Whitney test for non-
parametric analyses when a high coefficient of variation was ob-
served. A type I error rate for each test was set at 5%.
Results
Cervical T Cells: Isolation and Phenotype
23 HIV-infected women enrolled in the study and pro-
vided at least two cytobrush specimens (Table 1). The
study group overall was clinically stable, with a mean
CD41 T cell count of 470 cells/ml (median 450 cells/ml).
From the evaluable cervical cytobrush specimens, 10,000–
2,500,000 mononuclear cells were isolated. No mononu-
clear cells were detected in four patients, one of whose
physical deformity rendered pelvic examination difficult.
Eight subjects presented with vaginal candidiasis and two
with cervical dysplasia during the study. These events had
no impact on the ability to isolate mononuclear cells from
the cytobrushes, but in the case of vaginal candidiasis, the
growth of T cells in culture was impaired.
By cytofluorimetric analysis of fresh, filtered cytobrush
specimens, CD31 T cells commonly comprised <5% of
the mononuclear cell population (Fig. 1 A) but could pro-
liferate upon antigen-specific stimulation to purified CD41
or CD81 T cell populations (Fig. 1 B). Of these, typically
,2% were CD41 or CD81 T cells, as shown in Fig. 1 A in
two representative donors. The CD32CD161 NK cells
were present in variable frequencies, ranging from 0–71%
(median 23%) of the five donors examined. Because the
T cells were few in the initial specimen, the phenotype of
the T cells isolated on the day of collection did not predict
the ability to later demonstrate CD81 or CD41 cytolytic
activity in cell lines or clones.
We observed growth in wells containing cervical mono-
nuclear cells after 1–2 wk in culture in 19 of the 23 donors,
and in 64 of 108 (59%) specimens in the 19 donors over a
mean of 5.7 (median 5.5) visits (Table 1). Of the 57 speci-
mens that were not evaluable among the 23 women,
,10,000 mononuclear cells were enumerated after the
density centrifugation in 23 (40%), no growth was ob-
served in wells upon antigen stimulation in 26 (46%), and
contamination with yeast was noted within 2–5 d after cul-
ture in 8 (14%).
Cytolytic Responses
Although freshly activated HIV-1-specific CTL can be
found in peripheral blood of seropositive individuals, with
so few T cells present in the cervical specimens we opted to
test only antigen-stimulated cervical T cells for their ability
to recognize and lyse autologous target cells expressing
HIV-1 gene products. Experiments in 6 donors are repre-
sented in Fig. 2 and in the aforementioned 19 donors are
summarized in Table 1. HIV-specific cytolytic T cells were
detected at E/T of 1:1 to 5:1 in nearly two-thirds (12/19,
63%) of patients with at least one evaluable specimen, and
in over one-third (25/64, 39%) of the evaluable specimens
(Table 1). In decreasing order of frequency, lytic activity
was directed against autologous target cells expressing HIV-1
Env (9/19, 47%), Gag (6/19, 32%), and Pol (4/19, 21%).
In five patients, CTL responses were detected against more
than one gene product. In addition to HIV-1-specific lytic
activity, 17/62 cervical specimens (10 of the 19 donors)
contained NK cytolytic responses against the target cell
line, K562, with specific lysis ranging from 0–71% at an E/T
of 4:1. By contrast we tested similarly 5 HIV-1-uninfected
women for the presence of cervical HIV-1 CTL, and lysis
of autologous B-LCL infected with rVV (vPE-16, vDK-1,
or vRT) by the antigen-stimulated cell lines was ,5%.
These results indicated that the in vitro stimulation method
is unlikely to prime de novo cytolytic responses.
Figure 1. T lymphocytes in fresh cervical preparations and following
clonal expansion. Two-color cytofluorimetric analysis of freshly isolated
cervical mononuclear cells (A) and cervical CTL clones (B) obtained from
HIV-1-infected women: volunteer 737 (A, upper panels), volunteer 747
(A, lower panels), and volunteer 710 (B, both panels). Left-hand plots repre-
sent the two antibody isotype controls (IgG1 FITC and IgG2a PE). (A)
Middle plots demonstrate expression of CD3 (FL1) and CD16 (FL2). Sur-
face expression of CD4 (FL1) and CD8 (FL2) are shown in A (right-hand
plots) and B (middle plots). TCRab (FL1) and TCRgd (FL2) are shown in
B (right-hand plot).297 Musey et al.
To explore factors associated with the presence of HIV-
specific CTL, we stratified by the proportion of evaluable
specimens and the mean CD41 count of the subjects dur-
ing the study period. Volunteers in whom at least 50% of
cervical specimens contained sufficient cells for in vitro
stimulation were no more likely to exhibit cytotoxic re-
sponses (P 5 0.16) or have high (>500 cells/ml) CD41 T
cell responses (P 5 0.6). The ability to detect HIV-1-spe-
cific CTL was significantly greater in patients with CD41
counts >500 cells/ml than in those with ,500 cells/ml (8/8
vs 4/11, respectively, P 5 0.008) (Table 1). Moreover, the
presence of HIV-1 gag-specific CTL was strongly associ-
ated with a higher CD41 count (P 5 0.006). The median
CD41 count was 698 cell/ml in those subjects with a Gag-
specific CTL in comparison to a median of 356 cells/ml in
those lacking a Gag-specific response. These results imply
that women with relatively intact immunity may be more
likely to mount a mucosal immune response to HIV infec-
tion.
To examine the persistence of specific CTL in the cervix,
we sampled the infected volunteers at monthly 4–8-wk in-
tervals. HIV-1-specific cytolytic responses directed against
the three HIV-1 structural gene products were intermittent
in most subjects when tested after one cycle of in vitro
stimulation at low E/T (5:1 to 10:1) (Fig. 2 and Table 1).
Some donors such as 710 and 738 demonstrated frequent
CTL to more than one gene product (Fig. 2). An HIV-1
Gag-specific CTL response predominated in donor 741,
while a Pol-specific response was substituted by an Env-
and Gag-specific response in Donor 709. Upon review of
the history and physical findings recorded at each visit dur-
ing which specimens were collected, there were no obvi-
ous changes in clinical disease or cervical inflammation that
accounted for the variability in CTL responses. In addition,
positive CTL responses were detected repeatedly in some
volunteers (no. 710, 738, 709, and 741 in Fig. 2) during
various parts of the menstrual cycle (midfollicular to luteal
phase) except during menstruation, suggesting that detec-
tion of such responses was not influenced by the reproduc-
tive cycle.
Comparison of Cervical T Cell Populations Obtained by 
Biopsy and Cytobrush
To compare the cell population extracted from a cervical
cytobrush and an endocervical biopsy, simultaneous cervi-
cal cytobrush and biopsy specimens were obtained from two
patients. In the case of the biopsies, the tissue was exten-
sively washed before separation of the mononuclear cells to
prevent contamination by blood cells. The mononuclear
cell yields from the cervical biopsies were low (,10,000),
which did not permit cytofluorometric analysis on the ini-
tial analysis. After antigen-specific stimulation, a compari-
son of mononuclear cell phenotypes was performed in one
donor, and cytolytic responses in both donors. In donor
775, the mononuclear cells expanded from the brush and
biopsy after a 14-d stimulation were analyzed phenotypi-
cally by flow cytometry, which demonstrated 95 and 98%
of the cells as CD41, ,1 and 3% as CD81, 99 and 98% as
TCRa/b1, ,1 and ,1% as TCR g/d1, and 20 and 11%
as MLA-11, respectively. In both the cytobrush and biopsy
specimens from the two donors, low level Env-specific lysis
was detected at E/T 5:1 in patient 775, 10 and 16%; and in
patient 708, 18 and 16%, respectively. These results indi-
cate a relative concordance in the cell phenotype and cy-
tolytic responses in the cervical cytobrush and biopsy spec-
imens.
Analysis of Cervical CTL Clones: Phenotype, MHC 
Restriction, and Epitope Specificity
To determine the phenotype, MHC restriction, and
epitope specificity of the mucosal CTL, we generated
clones from cell lines that demonstrated HIV-specific lytic
activity. As indicated in Table 1, Env-specific clones were
established from four donors, Gag-specific clones from three
donors, and Pol-specific clones from three donors. By flow
cytometry (Fig. 1 B), the cell lines or clones examined were
CD31 (median 95%), TCRab1 (median 96%), TCRgd2
(median 1%), CD162 (median 1%), and MLA-12 (median
Figure 2. Cervical CTL are detected intermittently in HIV-infected
females. The graphs depict responses in six HIV-1-infected adult females
(donor number at upper right) tested at 4–8 weekly intervals. Percent spe-
cific lysis directed against autologous B-LCL expressing either Env (vPE-16)
(open bar), Gag (vDK-1) (black bar), or Pol (vRT) (lined bar) is represented
at an E/T ranging from 1:1 to 5:1. Lysis of the control target cells infected
with vaccinia alone was ,5% in each experiment and is not shown.298 HIV-1-Specific Cervical Cytotoxic T Lymphocytes
4%). All clones with specificity for HIV-1 Env were phe-
notypically CD41 cells, and those with specificity for either
HIV-1 Gag or Pol were CD81 cells.
CD41 Cervical Lymphocytes Mediate HIV-1 Env-Specific
Lysis. Clonal expansion of Env-specific CTL was per-
formed in four donors. In all cases, the clones generated
were CD41 by flow cytometric analysis (see Fig. 1 B for
example in donor 710). To determine the envelope region
containing the CTL epitope, the CTL clones in two do-
nors were tested for lysis of autologous B-LCL infected
with recombinant vaccinia containing serial truncations of
the env gene (Table 2). Five clones from donor 738 and
two clones from 708 recognized and lysed autologous tar-
gets infected with vPE16 and vPE17 but not vPE18, vPE8,
vPE21, and vPE22 (Table 2). These results indicate that the
CTL epitope recognized by both donors was within the
gp41 region of HIV-1 envelope.
To assess the ability of the gp41-specific CTL clones to
recognize and lyse HIV-1-infected targets, the two clones
from donor 708 were tested for cytolysis of CD4-trans-
duced B-LCL infected with either HIV-1LAI, or one of
two primary low passage HIV-1 isolates, 1002 or 1005, or
the uninfected control target. The clones lysed autologous
targets infected with all three HIV-1 isolates but not the
uninfected control targets (Fig. 3). The clones also lysed the
partially mismatched targets (donor 738) but not the com-
pletely mismatched targets (donors RML and SCHU), in-
dicating MHC class II restriction to either DR1 or DQ1
(Fig. 3). Additional studies to specifically define the class II
haplotype were not performed. These studies indicate that
CD41 CTL are present in the cervix of HIV-infected
women which are capable of killing HIV-1-infected cells.
CD81 Cytolytic Cells from the Cervix. In donor 738,
four CD81 clones were derived from the cervical cell line
at visit 8 (Fig. 2). These clones recognized and lysed targets
expressing HIV-1 Pol with a specific lysis ranging from 41-
61% at an E/T of 3:1 (Fig. 4 A). To determine the MHC
restriction patterns of these CTL clones, cytolysis of vRT-
infected B-LCL partially matched at MHC class I loci was
compared to vRT-infected autologous B-LCL. As shown
in Fig. 4 A, lysis of the Pol-specific target cells was re-
stricted to HLA-A2, with comparable lysis of targets from
donors 115 (allo-1) and 5224 (allo-2) who share this haplo-
type. To identify the epitope recognized by the MHC-
restricted CTL clones, we tested two nonamer peptides pre-
viously reported to be associated with HLA-A2-restricted
HIV-1 Pol CTL (24). The 4 clones lysed autologous targets
pulsed with the synthetic peptide spanning aa 476-484 but
not the peptide spanning aa 346-354 of the Pol region (Fig.
4 B). To ascertain the ability of these CTL clones to lyse
not only target cells expressing Pol through infection with
recombinant vaccinia or pulsing with peptides, but also in-
fected with HIV-1, we tested 4 clones against autologous
B-LCL targets infected with either HIV-1LAI or one of two
primary HIV-1 isolates obtained from PBMC co-cultures
of recently infected patients. As shown in Fig. 4 C, lysis by
the four clones was observed at an E/T of 3:1 against tar-
gets infected with the laboratory-adapted strain HIV-1LAI
(49, 38, 39, and 22%), but not against targets infected with
the two primary isolates (specific lysis ,1%) or against the
control uninfected targets (lysis <1%). In summary, these
experiments demonstrate that the HLA-A2-restricted cer-
vical CD81CTL clones derived from this subject recognize
a known epitope within HIV-1 Pol characteristic of pe-
ripheral blood CTL, and that the mucosal CD81 CTL, in
Table 2. CD41 CTL Clones from the Cervix Recognize
HIV-1 Env gp41
% Specific Lysis of Autologous
Targets Infected with rVV*
vPE16
0-851aa
vPE17
0-747aa
vPE18
0-635aa
vPE8
0-502aa
vPE21
0-287aa
vPE22
0-204aa
Donor 738‡
C7 18 24 2 5 ,1 ,1
C9 23 40 5 6 8 5
C17 24 47 2 6 3 3
C18 11 43 6 6 7 2
C24 20 45 1 5 5 3
Donor 708‡
C10 18 13 ,1 ,1 ,1N D
C18 19 15 ,1 ,1 ,1N D
* Tested at an E/T of 5:1 against autologous B-LCL infected with re-
combinant vaccinia expressing serial truncations of HIV-1 envelope.
Lysis of the vaccinia control targets ranged from ,1-3%.
‡Clones were generated from cervical cytobrushes obtained at visit 4
(Figure 2) for each donor.
Figure 3. CD41 cervical CTL clones from subject 708 lyse HIV-
1-infected cells (E/T of 5:1). HIV-1 Env-specific clones lyse HIV-1-infected
autologous and MHC class II partially mismatched (donor 738) B-LCL
but not MHC class II completely mismatched (donors RML and SCHU)
B-LCL or HIV-1-uninfected cells. The CTL clones recognize epitopes
expressed by the laboratory-adapted strain, HIV-1LAI, and two primary
HIV-1 isolates, no. 1002 and no. 1005.299 Musey et al.
contrast to the mucosal CD41 CTL, may function to de-
stroy some but not all HIV-1 strains.
Patient 710 had a vigorous Env- and Gag-specific CTL
response during the majority of monthly visits (Fig. 2). To
determine the breadth of CD81 CTL epitope specificity,
we chose to clone the Gag-specific cervical CTL lines from
visits 8 and 11. Three CD81 CTL clones derived from the
cytobrush specimen taken on visit 8 (Fig. 1 B) and six clones
from visit 11 demonstrated lytic activity to Gag-expressing
autologous B-LCL (Table 3). As shown in Fig. 5, A and B,
lytic activity of these CD81 clones was restricted by either
class I HLA-B14 or HLA-B27. All cervical-derived clones
recognized targets expressing Gag epitopes within the p24
region: the B14-restricted clones lysed targets pulsed with
the 20-mer spanning aa 290-309, and the B27-restricted
clones, the 20-mer spanning aa 160-179 (Table 3). Thus,
the patterns of gag epitope recognition in the cervical mu-
cosa were consistent in the two time periods separated by a
four month interval.
Comparison of the CTL Repertoire in Cervix and Peripheral
Blood. To compare the MHC restriction patterns and
epitope specificities of the CTL derived from the cervical
mucosa with that from peripheral blood, we also estab-
lished gag-specific CTL clones from PBMC obtained from
patient 710 at visit 8. Six CD81 gag-specific CTL clones
derived from the peripheral blood were restricted by the
same class I HLA haplotypes, B14 and B27, as in the cervi-
cal clones derived from visit 8 and 11 (see Fig. 5 for repre-
sentative experiments in four clones). Four blood clones
were tested in more detail for epitope specificity. Two of
the four shared the same epitope recognition patterns (Ta-
ble 3): HLA-B14-restricted CTL clone 1A8 lysed p24 pep-
tide 20 (aa 290-309), and HLA-B27-restricted clone 4B11
lysed peptide 7 (aa 160-179). However, two other periph-
eral blood clones demonstrated different epitope specificities:
the B14-restricted 4F10 clone recognized the p24 peptide 5
(aa 140-159) and the B27-restricted 1H8 recognized an
epitope within the p17 region, as evidenced by ,1% lysis
of the overlapping p24 20-mer peptides, and 43% lysis of
the autologous target infected with vp1290 expressing Gag
p17 at an E/T of 4:1. These results indicate that the MHC
restriction patterns and epitope specificities of the mucosal
CTL may be similar to those of the systemic CTL.
To address this issue in another donor, subject 909, we
examined the CTL repertoire from the cervix and blood
obtained on the same visit. HIV-1-specific CTL were de-
tected recognizing HIV-1 Gag but not Env or Pol in both
mucosal and systemic compartments. Eight CD81 lytic
clones were generated from the cervix and five from blood,
all of which recognized HIV-1 gag p24 (Table 4). The cer-
vical clones were restricted by HLA-B57, with specific lysis
of the partially mismatched Gag-expressing targets sharing
HLA-B57 ranging from 37–58% at E/T of 5:1. Of the 5
peripheral blood Gag-specific clones, only 3 (2B2, 4B10,
and 4C7) were restricted by HLA-B57. All eight cervical
clones and the three HLA-B57 peripheral blood clones
(2B2, 4B10, and 4C7) recognized the Gag p24 20-mer
spanning aa 160-79 (Table 4). PBL-derived clones 3B9 and
3A3 lysed vp1289 (specific lysis 75% and 74%, respec-
tively), a recombinant vaccinia expressing Gag p24, but not
vp1290 (specific lysis 5% and ,1%, respectively) expressing
Gag p17. Additional studies indicated recognition and lysis
by clones 3B9 and 3A3 of a p24 gag peptide (LADP788.21)
spanning aa 333-352 (26% and 16% specific lysis, respec-
tively). The findings in donor 909 together with those in
710 above indicate that the CTL repertoire in the cervix is
commonly found in peripheral blood of naturally infected
women.
Discussion
This investigation provides the first evidence that HIV-
1-specific cytotoxic T cells are present in the cervical mu-
cosa of infected women. Cervical CTL were detected at
least once in nearly two-thirds (63%) of the subjects tested
and in approximately half (47%) of their specimens with re-
peated examinations (Table 1), which indicates that muco-
Figure 4. Cervical CTL clones derived from subject 738 (visit 8) are
restricted by HLA-A2 and recognize targets expressing HIV-1 Pol aa 476-
484 or HIV-1-infected cells. (A) Specific lysis of autologous and MHC
class I partially matched allogeneic B-LCL infected with either vRT or
the control, vSC-8, at an E/T 3:1. Serological HLA class I typing for the
donors are the following: autologous, (A2,74, B58,63, Bw4,w6); allo-1,
(A2,28,B44,14,Bw4,w6); allo-2, (A2,B27,44,Bw4); allo-3, (A23,74,B70,57,
Bw4,w6). (B) Lysis by clones of autologous B-LCL pulsed with synthetic
peptides spanning Pol amino acid region 346-354 (VIYQYMDDL) and
476-484 (ILKEPVHGV) at an E/T of 3:1. C. Lysis at E/T of 3:1 of HIV-
1-infected and uninfected autologous B-LCL. Targets were infected with
either HIV-1LAI or one of two primary patient isolates, no. 1002 or no.
1005.300 HIV-1-Specific Cervical Cytotoxic T Lymphocytes
sal cytolytic responses are common in asymptomatic HIV-
infected individuals. Both CD41 and CD81 T cells mediate
the MHC-restricted cytolytic activity, which can be di-
rected to one or more epitopes within HIV-1 proteins en-
coded by env, gag, or pol, and can recognize and lyse HIV-
1-infected cells. Thus, HIV-1 infection induces not only a
profound CTL response in peripheral blood, but also in tis-
sues reservoirs such as lymph nodes (Musey, manuscript in
preparation) or other lymphoid organs (25), central nervous
system (26), respiratory tract (27), and mucosal surfaces.
Sampling by the cytobrush method to investigate cellular
immunity in the cervix offers the advantages of being well-
tolerated, non-invasive, inexpensive and practical. Because
the procedure occasionally can cause bleeding, a number of
precautions were implemented in this study to avoid con-
tamination of the cervical specimens with blood. These in-
cluded collection from volunteers only at times when they
were not menstruating or had no evidence of epithelial dis-
ruption, sampling for this study before other procedures,
rotating the cytobrush gently only one complete turn, and
rejecting samples with visible blood or microscopic RBC.
Thus, we believe that our samples were mucosal in origin
and not tainted with blood. The concordance of the find-
ings from the cytobrush specimens with those from the
cervical biopsy with respect to cell phenotype and cytolytic
function further support the mucosal derivation of these
cells and is consistent with previous reports (8). Also, our
findings in HIV-1-infected humans are similar to those pre-
viously observed by Lohman and colleagues (7), who re-
ported SIV-specific cytotoxic T lymphocytes in the vaginal
mucosa of infected monkeys.
The HIV-1-specific T cells in the cervical cytobrush
specimens are likely derived from an intraepithelial lympho-
cyte population. These originate either directly from pri-
mary lymphoid tissue, similar to gastrointestinal intraepithe-
lial cells which survey mucosal pathogens, or more likely
from memory and effector lymphocytes generated from na-
ive cells in secondary lymphoid organs which localize to
epithelial sites upon antigenic stimulation. The effector T cells
exhibited the TCRab1 rather than the TCRgd1 pheno-
type (Fig. 1), which is consistent with CTL found in the
cervicovaginal epithelium of SIV-infected macaques (7)
and in some cases with intraepithelial gastrointestinal T
cells (28). The low level of surface expression of the human
mucosal lymphocyte antigen 1 (CD103), an alpha E beta 7
integrin, on mucosal T cells from both the cytobrush and
Table 3. Comparison of CTL Responses in the Cervix and Peripheral Blood in Donor 710*
CTL clone
% Specific Lysis*
Vac
control
vDK
(gag)
v1290
(p17)
p24 peptide 5§
aa140-159
p24 peptide 7i
aa160-179
p24 peptide 20¶¦
aa290-309
Cervical-derived visit 8
8D4 (HLA-B14)‡ 02 5 N D 4 4 3 6
8B3 (HLA-B27) 0 44 ND 4 55 2
6G11 (HLA-B27) 0 33 ND 0 38 3
Cervical-derived visit 11
1F2 (HLA-B14) 0 33 ND 0 0 54
1F6 (HLA-B14) 0 41 ND 0 0 61
1H12 (HLA-B14) 0 45 ND 0 0 49
4A10 (HLA-B14) 0 50 ND 0 0 57
3G7 (HLA-B27) 0 23 ND 0 37 0
4B12 (HLA-B27) 0 24 ND 0 43 0
Blood-derived, visit 8
1A8 (HLA-B14) 0 45 0 5 4 51
4F10 (HLA-B14) 1 52 ND 60 3 0
4B11 (HLA-B27) 1 81 ND 3 30 ND
1H8 (HLA-B27) 0 55 43 0 0 0
*Specific lysis of autologous B-LCL infected with either vaccinia control, vDK expressing HIV-1LAI Gag, or v1290 containing Gag p17, or pulsed
with synthetic 20-mers spanning the p24 region. PBMC clones were tested at E/T of 4:1, cervical clones from visit 8 at E/T of 3:1, and cervical
clones from visit 11 at E/T of 5:1.
‡Class I HLA restriction, see also Fig. 4.
§p24 Peptide 5, aa 140-159: GQMVHQAISPRTLNAWVKVV.
ip24 Peptide 7, aa 160-179: EEKAFSPEVIPMFSALSEGA.
¶p24 Peptide 20, aa 290-309: PKEPFRDYVDRFYKTLRAEQAS.301 Musey et al.
biopsies differs from previous findings on T cells from
other mucosal sites such as the gut and lung (29–31). The
disparate results suggest that MLA-1 may be either differ-
entially regulated in the reproductive mucosa in contrast to
gut mucosa or its surface expression down-regulated as a
consequence of in vitro stimulation and differentiation into
effectors.
Although our study was not designed to evaluate cofac-
tors that may be associated with a CTL response in the cer-
vix, there were clearly differences in the ability to detect
CTL responses relative to CD41 count. These findings sug-
gest that the ability to mount a local immune response may
in part require a more intact immune system. This is con-
sistent with findings in other cervicovaginal infections such as
HPV (14, 32) and in neoplasia (32), whereby cellular im-
munodeficiency enhances progression of the cervical disease.
Moreover, one may anticipate that the failure to control vi-
ral replication by cervical CTL renders the HIV-1-infected
host more susceptible to local disease, such as HPV-associ-
ated cervical lesions and chronic vaginal candidiasis, which are
well-known to contribute significant morbidity in women
with declining CD41 counts (14, 33–36). Our results also
indicate that the presence of cervical cytolytic responses
may be intermittent, and the factors which control their
presence are not known. Potential influences currently un-
der study include the presence of HIV-1 or other infections
and host factors such as antigen presenting cell function,
the cytokine milieu, expression of adhesion molecules,
production of lymphocyte chemoattractants, and hormonal
cycling.
We provide two comparisons of the CTL repertoire in
the cervix and peripheral blood (Tables 3 and 4). These re-
sults suggest that the mucosal response may be narrower
than the systemic response. However, there may have been
sampling bias relative to the two compartments, and the
cloning efficiency of the T cells from the cervix may be
lower than from peripheral blood and thus the breadth of
responses in the cervix may have been missed. Although it
is impossible to completely discount this, the likelihood is
low since typically the percentage of clones generated from
Figure 5. Gag-specific CTL clones from the cervix and blood of Sub-
ject 710 are HLA class I restricted. Gag-specific clones were tested for ly-
sis of B-LCL infected with vDK-1 (Gag) or vSC-8 (control). Class I
MHC-restricted lysis by the clones is evidenced by lysis of the Gag-
expressing autologous B-LCL (A24,B14,B27) and B-LCL from donors
sharing one class I HLA allele as indicated on the figure. Lysis of the con-
trol targets infected with vSC-8 (vac-lac) were ,2% for all targets. (A)
Three cervical CTL clones from visit 8, tested at an E/T of 3:1. (B) Six
cervical CTL clones from visit 11, tested at an E/T of 5:1. (C) Four
PBMC-derived CTL clones from visit 8, tested at an E/T of 4:1.
Table 4. HIV-1 Gag-specific CD81 CTL Clones Derived
from the Cervix and Blood of Donor 909 Share Some but not
All Epitope Specificities
Clone
% Specific Lysis*
Vac
Control vDK
p24 aa
150-169
p24 aa
160-179
Cervical-derived
C4 0 47 0 60
C6 0 50 0 65
C12 0 41 0 52
C29 1 37 0 43
C35 0 58 0 76
C43 0 39 0 45
C48 0 41 0 52
C52 1 63 0 79
Blood-derived
2B2 0 42 0 55
4B10 0 33 0 35
4C7 0 52 3 78
3A3 1 55 0 4
3B9 0 40 0 0
*Specific lysis at E/T of 5:1 of targets either infected with the vaccinia
control or vDK expresssing HIV-1 gag, or pulsed with p24 gag peptide
6, aa150-169 (RTLNAWVKVVEEKAFSPEVI) or peptide 7, aa160-
179 (EEKAFSPEVIPMFSALSEGA). Clones 3A3 and 3B9 lysed the
p24 gag peptide spanning aa 333-352 (ILKALGPAATLEEMMT-
ACQG) at 26 and 16%, respectively.302 HIV-1-Specific Cervical Cytotoxic T Lymphocytes
the initial T cell yields were greater in the cervix than from
peripheral blood. Alternatively, the virus populations in the
cervix may be distinct from those in blood, which may
account for the differences in CTL repertoire in the two
compartments. In support of this, recent investigations dem-
onstrate heterogeneous viral populations in the cervix of
infected women which are not always reflected by virus in
PBMC (37). In addition, it has been postulated that HIV-1
infection like other infections may be associated with
clonal expansion followed by clonal exhaustion coincident
with an inability to clear virus (38), and these events may
be occurring locally at the site of infection and perhaps dis-
tinct from peripheral blood. Studies are in progress to ad-
dress these issues, particularly with regard to analysis of lo-
cal viral quasispecies and TCR usage by the HIV-1-specific
CTL clones, which should further elucidate the mechanism
by which mucosal CTL may control the evolution of spe-
cific HIV-1 variants.
In addition to MHC-restricted HIV-1-specific T cells,
we identified natural killer cell activity in the mucosal epi-
thelium (Table 1). When females are exposed to HIV-1 by
sexual contact, the first line of defense against HIV in the
genital mucosa likely are nonspecific effector mechanisms
such as NK cell activity. Our findings support this hypoth-
esis, with a variable number of NK cells found in the fresh
specimens and the majority of subjects containing NK cy-
tolytic activity upon in vitro culture. This may be followed
by the generation of antigen-specific immune responses,
such as specific antibody, IgA or IgG, which mediate at-
tachment, opsonization, neutralization or antibody-depen-
dent cellular cytotoxicity, as well as cytotoxic T lymphocytes.
Infected cells are likely to first encounter CTL effector re-
sponses in the draining lymph nodes, but the continued
presence of HIV-1-specific CTL may reflect the persis-
tence of antigen in the cervical mucosa.
What remains to be determined is the role these effector
cells play in controlling local HIV-1 infection and preven-
tion of viral transmission. Because these cells are capable of
destroying HIV-infected cells, their presence in the genital
area may serve to control viral replication and thus prevent
transmission to sexual partners. Moreover, these T cell re-
sponses can conceivably provide an important defense
against HIV-1 exposure and thus may be useful to elicit
with vaccines. Immunization strategies that target mucosal
sites may prove more effective if designed to elicit both an-
tibody and cellular responses locally. Thus, this investiga-
tion provides new evidence that T cell responses in the
genital mucosa may be critical in the immune defense
against HIV-1, and future studies to elucidate their role in
protecting against transmission and controlling early infec-
tion should be further explored.
We are grateful for the assistance and support provided by Lyn Burke, Ellen Blackstone, the staff at North-
west Family Center, as well as for the time and dedication provided by the volunteers in this study.
This investigation was supported in part by National Institutes of Health grants AI 35605, AI 27757, and AI
07140. L. Musey was a recipient of a IARTP Fellowship (D43TW00007).
Address correspondence to Dr. M. Juliana McElrath at the Fred Hutchinson Cancer Research Center, Clin-
ical Research Division, M-115, 1124 Columbia St., Seattle, WA 98104.
Received for publication 2 October 1996 and in revised form 7 November 1996.
References
1. Mertens, T.E., and A. Burton. 1996. Estimates and trends of
the HIV/AIDS epidemic. AIDS. 10(Suppl. A):S221–S228.
2. Kutteh, W.H., R.P. Edwards, A.C. Menge, and J. Mestecky.
1993. IgA immunity in female reproductive tract secretions.
In Local Immunity in Reproduction Tract Tissues. Oxford
University Press. 229–243.
3. McGhee, J.R., and J. Mestecky. 1992. The mucosal immune
system in HIV infection and prospects for mucosal immunity
to AIDS. In AIDS Research Review. 2:289–312.
4. Nielsen, K., P. Boyer, M. Dillon, D. Wafer, L.S. Wei, E.
Garratty, R.E. Dickover, and Y.J. Bryson. 1996. Presence of
human immunodeficiency virus (HIV) type 1 and HIV-1-spe-
cific antibodies in cervicovaginal secretions of infected moth-
ers and in the gastric aspirates of their infants.  J Infect. Dis.
173:1001–1004.
5. Kozlowski, P.A., K.P. Black, L. Shen, and S. Jackson. 1995.
High prevalence of serum IgA HIV-1 infection-enhancing
antibodies in HIV-infected persons. Masking by IgG. J Immu-
nol. 154:6163–6173.
6. Janoff, E.N., S.M. Wahl, K. Thomas, and P.D. Smith. 1995.
Modulation of human immunodeficiency virus type 1 infec-
tion of human monocytes by IgA. J. Infect. Dis. 172:855–858.
7. Lohman, B.L., C.J. Miller, and M.B. McChesney. 1995. An-
tiviral cytotoxic T lymphocytes in vaginal mucosa of simian
immunodeficiency virus-infected rhesus macaques. J. Immu-
nol. 155:5855–5860.
8. Moscicki, A.-B., S.D. Hunter, S. Garland, M. Quinn, S.M.
Crowe, K. Shortman, and D. Stites. 1995. A simple method
for the propagation of cervical lymphocytes. Clin. Diag. Lab.
Immunol. 2:40–43.
9. Crowley-Nowick, P.A., M. Bell, R.P. Edwards, D. McCal-
lister, H.Gore, A. Kanbour-Shakir, J. Mestecky, and E.E.
Partridge. 1995. Normal uterine cervix: characterization of
isolated lymphocyte phenotypes and immunoglobulin secre-
tion. Am. J. Reprod. Immunol. 34:241–247.
10. Hussain, L.A., C.G. Kelly, R. Fellowes, E.M. Hecht, J. Wil-303 Musey et al.
son, M. Chapman, and T. Lehner. 1992. Expression and
gene transcript of Fc receptors for IgG, HLA class II antigens
and Langerhans cells in human cervico-vaginal epithelium.
Clin. Exp. Immunol. 90:530–538.
11. McKenzie, J., A. King, J. Hare, T. Fulford, B. Wilson, and
M. Stanley. 1991. Immunocytochemical characterization of
large granular lymphocytes in normal cervix and HPV associ-
ated disease. J. Pathol. 165:75–80.
12. Poppe, W.A.J., P.S. Ide, M.P.G. Drijkoningen, J.M. Lauw-
eryns, and F.A. Van Assche. 1995. Tobacco smoking impairs
the local immunosurveillance in the uterine cervix. Gynecol.
Obstet. Invest. 39:34–38.
13. Garzetti, G.G., A. Ciavaettini, L. Butini, A. Vecchi, and M.
Montroni. 1995. Cervical dysplasia in HIV-seropositive
women: role of human papillomavirus infection and immune
status. Gynecol. Obstet. Invest. 40:52–56.
14. Fukuda, K., T. Hachisuga, S. Nakamura, N. Matsuo, T.
Iwasaka, and H. Sugimori. 1993. Local immune response in
persistent cervical dysplasia. Obstet. Gyn. 82:941–945.
15. Bell, M.C., R.P. Edwards, E.E. Partridge, K. Kuykendall, W.
Conner, H. Gore, E. Turbat-Herrera, and P.A. Crowley-
Nowick. 1995. CD81 lymphocytes are recruited to neoplas-
tic cervix.  J. Clin. Immunol. 15:130–136.
16. Olaitan, A., M.A. Johnson, A. MacLean, and L.W. Poulter.
1996. The distribution of immunocompetent cells in the gen-
ital tract of HIV-positive women. AIDS (Phila). 10:759–764.
17. Earl, P.L., A.W. Hugin, and B. Moss. 1990. Removal of
cryptic poxvirus transcription termination signals from the
human immunodeficiency virus type 1 envelope gene en-
hances expression of a recombinant vaccinia virus. J. Virol.
64:2448–2451.
18. Earl, P.L., S. Koenig, and B. Moss. 1991. Biological and im-
munological properties of human immunodeficiency virus
type 1 envelope glycoprotein: analysis of protein with trunca-
tions and deletions expressed by recombinant vaccinia vi-
ruses. J.Virol. 65:31–41.
19. Flexner, C., S.S. Broyles, P. Earl, S. Chakrabarti, and B.
Moss. 1988. Characterization of human immunodeficiency
virus gag/pol gene products expressed by recombinant vac-
cinia viruses. Virology. 166:339–349.
20. Chakrabarti, S., K. Brechling, and B. Moss. 1985. Vaccinia
virus expressing vector: co-expression of b-galactosidase pro-
vides visual screening of recombinant virus plaques. Mol.
Cell. Biol. 5:3403–3409.
21. McFarland, E.J., T.J. Curiel, D.J. Schoen, M.E. Rosandich,
R.T. Schooley, and D.R. Kuritzkes. 1993. Cytotoxic T lym-
phocyte line specific for the human immunodeficiency virus
type 1 gag and reverse transcriptase derived from a vertically
infected child. J. Infect. Dis. 167:719–23.
22. McElrath, M.J., M. Rabin, M. Hoffman, S. Klucking, J.V.
Garcia, and P.D. Greenberg. 1994. Evaluation of human
immunodeficiency virus type 1 (HIV-1)-specific cytotoxic
T-lymphocyte responses utilizing B-lymphoblastoid cell lines
transduced with the CD4 gene and infected with HIV-1. J.
Virol. 68:5074–5083.
23. Akridge, R.E., L.K.M. Oyafuso, and S.A. Reed.1994. IL-10
is induced during HIV-1 infection and is capable of decreas-
ing viral replication in human macrophages. J. Immunol. 153:
5782–5789.
24. Tsomides, T.J., B.D. Walker, and H.N. Eisen. 1991. An op-
timal viral peptide recognized by CD81 T cells bind very
tightly to the restricting class I major histocompatibility com-
plex protein on intact cells but not the purified class I protein.
Proc. Natl. Acad. Sci. USA. 88:11276–11278.
25. Hadida, F., A. Parrot, M.P. Kieny, B. Sadat-Sowti, C. May-
aud, P. Debre, and B. Autran. 1992. Carboxyl-terminal and
central regions of human immunodeficiency virus-1 nef rec-
ognized by cytotoxic T lymphocytes from the lymphoid or-
gans. An in vitro limiting dilution analysis. J.Clin. Invest. 89:
53–60.
26. Jassoy, C., R.P. Johnson, B.A. Navia, J. Worth, and B.D.
Walker. 1992. Detection of a vigorous HIV-1 specific cyto-
toxic T lymphocyte response in cerebrospinal fluid from in-
fected persons with AIDS dementia complex. J. Immunol.
149:3113–3119.
27. Plata, F., B. Autran, L.P. Martins, S. Wain-Hobson, M.
Raphael, C. Mayaud, M. Denis, J.M. Guillon, and P. Debre.
1987. AIDS virus-specific cytotoxic T lymphocytes in lung
disorders. Nature (Lond.). 328:348–351.
28. Fujihashi, K., M. Yamamoto, J.R. McGhee, and H. Kiyono.
1993. abT cell receptor-positive intraepithelial lymphocytes
with CD41, CD8- and CD41, CD81 phenotypes from orally
immunized mice provide Th2-like function for B cell re-
sponses. J. Immunol. 151:6681–6691.
29. Coleman, N., and M.A. Stanley. 1994. Characterization and
functional analysis of the expression of vascular adhesion mol-
ecules in human papillomavirus-related disease of the cervix.
Cancer (Phila). 74:884–892.
30. Shaw, S.K. and M.B. Brenner. 1995. The beta 7 integrins in
mucosal homing and retention. Semin. Immunol. 7:335–342.
31. Brew, R., D.C. West, J. Burthem, and S.E. Christmas. 1995.
Expression of the human mucosal lymphocyte antigen,
HML-1, by T cells activated with mitogen or specific antigen
in vitro. Scand. J. Immunol. 41:553–562.
32. Petry, K.U., D. Scheffel, U. Bode, T. Gabrysiak, H. Kochel,
E. Kupsch, M. Glaubitz, S. Niesert, H. Kuhnle, and I. Sche-
del. 1994. Cellular immunodeficiency enhances the progres-
sion of human papillomavirus-associated cervical lesions. Int.
J. Cancer. 57:836–840.
33. Korn, A.P., and D.V. Landers. 1995. Gynecologic disease in
women infected with human immunodeficiency virus type 1.
J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol. 9:361–370.
34. Maiman, M., R.G. Fruchter, L. Guy, S. Cuthill, P. Levine,
and E. Serur. 1993. Human immunodeficiency virus infec-
tion and invasive cervical carcinoma. Cancer (Phila). 71:402–406.
35. Powderly, W.G. Resistant candidiasis.1994. AIDS Res Hum
Retroviruses. 10:925–929.
36. Marte, C. 1992. Papanicolaou smear abnormalities in ambu-
latory care sites for women infected with the human immun-
odeficiency virus. Am. J. Obstet. Gynecol. 166:1232–1237.
37. Poss, M., H.L. Martin, J.K. Kreiss, L. Granville, B. Chohan,
P. Nyange, K. Mandaliya, and J. Overbaugh. 1995. Diversity
in virus populations from genital secretions and peripheral
blood from women recently infected with human immuno-
deficiency virus type 1.  J. Virol. 69:8118–8122.
38. Moskophidis, D., F. Lechner, H. Pircher, and R.M. Zinker-
nagel. 1993. Virus persistence in acutely infected immuno-
competent mice by exhaustion of antiviral cytotoxic effector
T cells. Nature (Lond.). 362:758–761.